Similarly, in hCD27 transgenic mice, varlilumab selectively strengthened CD8+ T-cell phenotypes in terms of activation, proliferation and cytotoxic state in lymphoid organs and tumor infiltrates, led to preferential depletion of suppressive Tregs, and generated durable and broad anti-tumor immunity [164]. Here, CD8A is linked to neoplasm.